The company is focused on developing high-throughput phenotype screening platforms and profiling chemical compounds across a large mutation and phenotype space. BiocipherX has extensive experience in integrating multi-omics data and designing and analyzing high-dimensional data sets. The resulting data can be used to predict drug performance, clinical outcomes, and mode-of-action and other parameters. In addition, the company is involved in the development of automation and robotic technology for running these assays.